Suven granted patents for neurodegenrative drug

Pharmaceutical firm Suven Life Sciences today said it has been granted one patent each by Australia and Eurasia for drug used in the treatment of neurodegenrative diseases.
Neurodegenrative diseases include Alzheimer's disease, Schizophrenia and Parkinson's disease.
In a BSE filing the company said that it has been granted "one product patent from Australia and one product patent from Eurasia corresponding to the new chemical entities for the treatment of disorders associated with neurodegenerative diseases".
These patents are valid until 2030 and 2029 respectively, the company said in a BSE filing.
Suven Life Sciences CEO Venkat Jasti said: "We are very pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS (central nervous system) arena that are being developed for cognitive disorders with high unmet medial need with huge market potential globally."

With these new patents, Suven has a total of 18 granted patents from Australia and 12 from Eurasia.
"These patents are exclusive intellectual property of Suven...Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-1 and Phase-2," Suven Life Sciences said.